Baldwin Brothers Inc. MA reduced its holdings in Merck & Co., Inc. (NYSE:MRK) by 0.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 199,871 shares of the company’s stock after selling 1,381 shares during the period. Merck & Co., Inc. accounts for approximately 2.6% of Baldwin Brothers Inc. MA’s portfolio, making the stock its 7th largest position. Baldwin Brothers Inc. MA’s holdings in Merck & Co., Inc. were worth $15,272,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Third Point LLC bought a new position in Merck & Co., Inc. in the 3rd quarter worth approximately $319,230,000. PointState Capital LP bought a new stake in shares of Merck & Co., Inc. during the third quarter valued at approximately $8,513,000. Port Capital LLC bought a new stake in shares of Merck & Co., Inc. during the third quarter valued at approximately $1,028,000. Green Valley Investors LLC bought a new stake in shares of Merck & Co., Inc. during the third quarter valued at approximately $31,418,000. Finally, Carnegie Capital Asset Management LLC increased its position in shares of Merck & Co., Inc. by 24.2% during the third quarter. Carnegie Capital Asset Management LLC now owns 36,248 shares of the company’s stock valued at $2,756,000 after purchasing an additional 7,068 shares during the period. 73.36% of the stock is currently owned by institutional investors.

In other Merck & Co., Inc. news, Chairman Kenneth C. Frazier sold 231,566 shares of the company’s stock in a transaction on Tuesday, February 5th. The stock was sold at an average price of $78.08, for a total value of $18,080,673.28. Following the sale, the chairman now directly owns 923,516 shares in the company, valued at $72,108,129.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Rita A. Karachun sold 64,662 shares of the company’s stock in a transaction on Thursday, February 14th. The shares were sold at an average price of $78.96, for a total value of $5,105,711.52. Following the completion of the sale, the vice president now owns 53,327 shares in the company, valued at $4,210,699.92. The disclosure for this sale can be found here. Insiders sold 1,094,632 shares of company stock worth $87,840,652 over the last quarter. Company insiders own 0.32% of the company’s stock.

A number of analysts have recently issued reports on the company. Zacks Investment Research upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $83.00 price objective on the stock in a research report on Friday, January 4th. Cantor Fitzgerald assumed coverage on Merck & Co., Inc. in a research report on Friday, February 22nd. They set an “overweight” rating and a $95.00 price objective on the stock. BMO Capital Markets restated a “hold” rating on shares of Merck & Co., Inc. in a research report on Tuesday, February 19th. Credit Suisse Group set a $86.00 price objective on Merck & Co., Inc. and gave the company a “buy” rating in a research report on Thursday, December 13th. Finally, Argus boosted their price objective on Merck & Co., Inc. to $95.00 and gave the company a “buy” rating in a research report on Wednesday, February 20th. Six analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $77.06.

Shares of NYSE:MRK opened at $82.29 on Thursday. Merck & Co., Inc. has a fifty-two week low of $52.83 and a fifty-two week high of $83.47. The firm has a market capitalization of $223.57 billion, a price-to-earnings ratio of 18.96, a P/E/G ratio of 2.01 and a beta of 0.62. The company has a current ratio of 1.17, a quick ratio of 0.92 and a debt-to-equity ratio of 0.74.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Friday, February 1st. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.01. Merck & Co., Inc. had a return on equity of 36.83% and a net margin of 14.71%. The firm had revenue of $11 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same period in the prior year, the business posted $0.98 earnings per share. The business’s revenue was up 5.4% compared to the same quarter last year. As a group, research analysts predict that Merck & Co., Inc. will post 4.65 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, April 5th. Shareholders of record on Friday, March 15th will be given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 2.67%. The ex-dividend date is Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 50.69%.

TRADEMARK VIOLATION WARNING: “Baldwin Brothers Inc. MA Has $15.27 Million Holdings in Merck & Co., Inc. (MRK)” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/baldwin-brothers-inc-ma-has-15-27-million-holdings-in-merck-co-inc-mrk/2922801.html.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Recommended Story: Bond

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.